Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07334444
Recruiting Observational

Optimizing the Management of OSA in Children With Down Syndrome

NCT07334444 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-03-19
Last updated
2026-01-12

Condition(s) studied

Obstructive Sleep Apnea

Study summary

The objective of this retrospective descriptive study is to assess current practices for the screening and surgical treatment of OSA in children with Down syndrome at the Strasbourg University Hospital and to disseminate a management algorithm in France.

Eligibility

Sex
ALL
Min age
0 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Child with Down syndrome, * Aged between 0 and 17 years, * Having been seen for an ENT consultation at the University Hospital or the Sleep Center of the University Hospital of Strasbourg between January 1, 2019, and December 31, 2024 Exclusion Criteria: \- Presence of a written objection in the medical file of the subject (and/or their representative) to the reuse of their data for scientific research purposes.

Primary outcome measure(s)

  • Apnea-hypopnea index (AHI) before and after surgery. — Day 1 before surgery and Day 1 after surgery
    The AHI is a number that indicates how many times per hour breathing is abnormal during sleep. It adds up: * Apneas → breathing stops completely * Hypopneas → breathing becomes much shallower Scores: * AHI \< 5 → normal * AHI between 5 and 15 → mild impairment * AHI between 15 and 30 → moderate impairment

Trial sites (1)

FacilityCityRegionStatus
Service d'ORL et de Chirurgie Cervico-faciale - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals Recruiting
Platelet and Autotransfusion Device in Cardiac Surgery Recruiting
Stone Disease of the Urinary Tract in Children Recruiting
Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions Recruiting
Duration of Therapeutic Anticoagulation in Patients With Pulmonary Embolism Recruiting

Other trials for the same condition

Hypercapnic Burden in Adults With Obesity Undergoing Diagnostic Polysomnography for Suspected Obstructive Sleep Apnea Starting soon
Systematic Screening for Obstructive Sleep Apnea During Preoperative Consultation Using AI-preoperative Agents Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Active, not recruiting
Patients with Coronary Artery Disease or At High Cardiovascular Risk: Measuring Compliance with Treatment for Obstructive Sleep Apnea Syndrome Recruiting
Real-World Performance and Safety of Apneal Dx for Sleep Apnea Screening Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07334444 on ClinicalTrials.gov ↗ ← All trials in France